1357177-75-3

Upstream product

• 597577-80-5 ethyl {(4S)-4-[(benzyloxy)methyl]-2-oxo-1,3-oxazolidin-3-yl}acetate 
• 1357177-74-2 (4S)-4-[(benzyloxy)methyl]-3-(2-hydroxyethyl)-1,3-oxazolidin-2-one 
• 10387-40-3 potassium thioacetate 
• 23680-31-1 BOC-O-benzyl-L-serine 
• 79069-15-1 N-(tert-butyloxycarbonyl)-O-benzyl-L-serinol 
• 66866-45-3 C₂₀H₂₉NO₇ 
• 158612-99-8 (4S)-4-[(benzyloxy)methyl]-1,3-oxazolidin-2-one 

Downstream Products

• 729611-47-6 4-[(2-{(4S)-4-[(1E,3S)-3-hydroxy-4-(3-propylphenyl)but-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}ethyl)sulfanyl]butanoic acid 
• 729611-44-3 4-{[2-((4S)-4-{(1E,3S)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]but-1-enyl}-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}butanoic acid 
• 729611-42-1 4-[(2-{(4S)-4-[(1E,3S)-4-(3-fluorophenyl)-3-hydroxybut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}ethyl)sulfanyl]butanoic acid 
• 494222-50-3 4-[(2-{(4S)-4-[(1E,3S)-4-(3-chlorophenyl)-3-hydroxybut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}ethyl)sulfanyl]butanoic acid 
• 729611-34-1 4-[(2-{(4S)-4-[(1E,3S)-4-(1,1'-biphenyl-3-yl)-3-hydroxybut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}ethyl)sulfanyl]butanoic acid 
• 729611-38-5 4-{[2-((4S)-4-{(1E,3S)-3-hydroxy-4-[3-(trifluoromethoxy)phenyl]but-1-enyl}-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}butanoic acid 
• 729611-48-7 4-{[2-((4S)-4-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}butanoic acid 
• 729611-46-5 4-[(2-{(4S)-4-[(1E,3S)-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}ethyl)sulfanyl]butanoic acid 

Relevant academic research and scientific papers

Synthesis and evaluation of novel modified γ-lactam prostanoids as EP4 subtype-selective agonists

To identify chemically and metabolically stable subtype-selective EP4 agonists, design and synthesis of a series of modified γ-lactam prostanoids has been continued. Prostanoids bearing 2-oxo-1,3-oxazolidine, 2-oxo-1,3-thiazolidine and 5-thioxopyrrolidine as a surrogate for the γ-hydroxycyclopentanone without a troublesome 11-hydroxy group were identified as highly subtype-selective EP4 agonists. Among the tested, several representative compounds demonstrated in vivo efficacy after oral dosing in rats. Their pharmacokinetic and structure-activity relationship studies are presented.